At the request of the Minister of Health, the Scientific Advisory Committee on Coronavirus (SCC) in yesterday's session evaluated the vaccination program, the availability of vaccines and the expected receipts of vaccines, the vaccination coverage rate of the population as well as the issue to date. side effects from vaccinations and reported severe thrombotic events.
From the suggestions submitted by the members of the TEU, it appears that:
- Unanimously the clear position that persons vaccinated with 1η dose of AstraZeneca vaccine, should proceed normally with 2η dose of the vaccine, provided that they did not occur after 1η dose any symptoms of serious side effects (thrombosis / thrombocytopenia syndrome). Therefore, these individuals are invited to attend normally for 2η dose of the vaccine, which is particularly important for their protection against the virus and its mutations.
- As far as his subject is concerned age restriction in the administration of the AstraZeneca vaccine, the majority of the members of the TEU, having taken into account the improved epidemiological picture, the availability of vaccines and the benefit of a smooth continuation of the vaccination program, Recommends recommendation for preference for mRNA technology vaccines (Pfizer / BioNTech and Moderna) for people aged 50 and under. Therefore, the Ministry of Health adopts the recommendation of the majority of the members and urges citizens under the age of 50 to choose a mRNA technology vaccine for their vaccination.
The Ministry of Health assures that it closely monitors developments and data emerging in Cyprus and internationally, as well as any new recommendations that may arise from Coreper, and is ready to regularly assess the course of the epidemiological picture of the country and extend the vaccination plan, and take all actions with the primary priority of safeguarding public health and the safety of citizens.